Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE: AZD8931 plus paclitaxel versus paclitaxel alone in previously treated metastatic gastric or gastro-oesophageal junction cancer
2011-005194-23Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapitinib, paclitaxel in gastric cancer (GC), esophagogastric junction cancer, sponsored by AstraZeneca. Started Jul 2012; status: terminated.
02
Drugs
sapitinibpaclitaxel
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2011-005194-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005194-23.